Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML patient cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below).

Each clinical case will be forwarded to the iCMLf expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are only accepted from clinicians. If individual patients have a specific question we encourage them to contact their healthcare provider.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Challenging case

  • Rafael Hurtado-Monroy
  • Rafael Hurtado-Monroy's Avatar Topic Author
2 months 1 week ago - 2 months 1 week ago #1827 by Rafael Hurtado-Monroy
Challenging case was created by Rafael Hurtado-Monroy
A 53 year old Mexican patient was send to our referral center for CML with typical CML by clinical and laboratory, but Ph was negative for all methods, however the cytogenetic study showed 45~47, XX, del(11)(q23)del (12))(p13, +20(cp15)/46XX(5).

In a period of two weeks she doubled the WBC count and spleen pain, G-IV anemia with blood transfusion required as well.

We started with hydroxyurea, however I would like to know other opinion of experts in regard treatment strategy, other than supportive therapy.
Last edit: 2 months 1 week ago by arlene.
  • Michele Baccarani
  • Michele Baccarani's Avatar Topic Author
2 months 1 week ago - 2 months 1 week ago #1828 by Michele Baccarani
Replied by Michele Baccarani on topic Challenging case
This could be a case of Ph+ BCR-ABL+ CML with a rare fusion transcript that cannot be detected by current PCR testing. Very rare, almost hypothetical, but worth of a trial of imatinib 400 mg once daily. If it works, it works very quickly, the cost of the generic is low and toxicity is negligible.

Deletions of the long arm of chromosome 11, though non specific, recur in several Phneg CMN. Some patients have responded to Ruxolitinib. If Imatinib fails, I would try Ruxo.

But I’m afraid that one should plan allogeneic stem cell transplantation, as soon as possible, if the patient is eligible, any donor but cord blood, myeloablative, with Cyclophosphamide after stem cell infusion.

Good Luck!
Last edit: 2 months 1 week ago by arlene.
Moderators: Melissa Davis-Bishop